Dr. Kendall was most recently president and CEO of ImmPACT BIO, a cell therapy company developing engineered T cells for the treatment of cancer. Prior, he was vice president of research at Kite Pharma, where he was responsible for the company’s research pipeline and development of CAR-T technologies. Dr. Kendall was also an executive director and head of oncology research at Amgen, where he directed a group of more than 90 scientists and was responsible for the development of the company’s oncology therapeutic strategy aligning research with other functions, including chemistry, protein sciences, medical translational sciences, development, and commercial. Among his many accomplishments at Amgen, Dr. Kendall initiated efforts that led to the development of the first true KRAS inhibitor, LUMAKRAS. Additionally, he led the research diligence and integration team for the Micromet acquisition integrating the Bi-Specific T-cell Engager (BiTE) platform into Amgen’s repertoire of therapeutic modalities, which became a cornerstone in the company’s immune-oncology efforts. He holds a bachelor of science degree from the University of California, Los Angeles, and a PhD from the University of California, Irvine, School of Medicine.